Safety Communication

The Pharmacy and Poisons Board (PPB) of Kenya regularly issues Safety Communications to safeguard public health by disseminating critical information regarding the safety, quality, and efficacy of health products and technologies. These communications, mandated by the Pharmacy and Poisons Act, Cap 244, serve as vital alerts to healthcare professionals and the public on issues ranging from product recalls and falsified medicines to adverse drug reactions and appropriate medication use. Recent examples include directives on the handling of high-alert medicines, warnings against the off-label use of certain compounds, and notices on prescription errors. Understanding and adhering to these safety communications is a fundamental professional obligation for all legal and medical practitioners involved in the pharmaceutical supply chain, ensuring compliance and mitigating risks to patient safety.

The landscape of pharmaceutical regulation in Kenya is dynamically shaped by the Pharmacy and Poisons Board (PPB), the principal drug regulatory authority established under the Pharmacy and Poisons Act, Cap 244 of the Laws of Kenya. A critical function of the PPB is the issuance of 'Safety Communications,' which are formal advisories designed to inform healthcare professionals, manufacturers, and the public about potential risks, quality defects, or misuse associated with medicinal products and health technologies. These communications are not merely informational; they carry significant regulatory weight, often necessitating specific actions from stakeholders to ensure patient safety and maintain public health standards.

These safety communications are a cornerstone of pharmacovigilance, reflecting the PPB's commitment to monitoring and responding to emerging safety concerns in the post-market phase of health products. The Board's proactive dissemination of such information is crucial for preventing harm, ensuring the continued efficacy of authorized products, and upholding the integrity of the pharmaceutical supply chain. For legal professionals, particularly those advising pharmaceutical companies, healthcare providers, or involved in medical malpractice litigation, a thorough understanding of these communications is indispensable for navigating regulatory compliance and assessing potential liabilities.

This article delves into the nature, legal basis, and practical implications of Safety Communications issued by the Pharmacy and Poisons Board Kenya. It will explore the statutory framework empowering the PPB, analyze recent examples of these communications, and highlight the critical role they play in the broader regulatory ecosystem, emphasizing the obligations they impose on practicing attorneys and their clients within the healthcare sector.

The legal foundation for the PPB's regulatory authority, including its power to issue safety communications, is firmly rooted in the Pharmacy and Poisons Act, Cap 244. This Act provides for the control of the profession of pharmacy and the trade in drugs and poisons, establishing the PPB as a body corporate responsible for overseeing compliance with safety standards, drug registration, and the control of poisons. The Board's mandate explicitly includes ensuring that all medicinal products manufactured in, imported into, or exported from Kenya conform to prescribed standards of quality, safety, and efficacy.

Central to this mandate is the function of pharmacovigilance, which involves the collection, management, assessment, analysis, and communication of safety information related to health products and technologies. The PPB is empowered to monitor and review the implementation of legislation on pharmaceutical products and to advise the Minister of Health on matters concerning the control and registration of medicinal products. This comprehensive statutory framework underpins the PPB's ability to issue various forms of safety communications, including Direct Healthcare Professional Communications (DHPCs), Additional Risk Minimization Measures (aRMMs), and public alerts, all aimed at protecting public health.

The Act also outlines provisions for the registration of pharmacists and pharmaceutical technologists, and the inspection of training institutions, further solidifying the PPB's role in maintaining high professional standards. The emphasis on continued conformity of medicinal products with set standards until their delivery to the end-user underscores the continuous nature of regulatory oversight, making safety communications a vital tool in this ongoing process.

Safety Communications from the PPB manifest in various forms, each tailored to the nature of the risk and the target audience. Recent examples illustrate the breadth of issues addressed. For instance, in 2026, the PPB issued a Safety Communication titled 'Right Drug, Right Dose, Right Patient: Ensuring good dispensing and administration practices to prevent medication errors,' targeting healthcare professionals (HCPs) and covering medicines and vaccines. This type of communication, often a DHPC, directly informs practitioners about best practices to mitigate common risks in clinical settings.

In 2025, the PPB issued several significant alerts, including 'Safety communication for healthcare providers: Additional Risk Minimization Measures (aRMM) for Roaccutane (Isotretinoin),' highlighting the need for specific precautions with high-risk medications. Another critical communication in 2025 was 'Handling Of High-Alert Medicines in the Facilities,' emphasizing the importance of stringent protocols for drugs with a high risk of causing significant harm when misused. Public alerts were also issued, such as 'Safety Alert for the Members of the Public on the Off-Label use of Semaglutide-containing Compounds for Weight Loss' and a 'Public alert on paracetamol use during pregnancy,' demonstrating the PPB's commitment to direct public engagement on critical health matters.

The PPB also issues 'Rapid Alerts' concerning substandard, falsified, or unregistered products. In 2024, such alerts included mandatory recalls for products like Efinox and Flamodip, and public alerts on falsified Ozempic (Semaglutide) pens and Benylin Pediatric cough syrup. These rapid alerts often lead to immediate market withdrawals or quarantine orders, underscoring the urgency and legal imperative for compliance by manufacturers, distributors, and pharmacies. The legal implications for non-compliance with these directives are severe, potentially leading to product liability claims, regulatory penalties, and reputational damage.

Beyond specific product-related alerts, the PPB also issues broader regulatory updates. For example, a February 2026 update highlighted that 22% of health products and technologies (HPTs) in circulation had not submitted renewal applications for their marketing authorizations by the December 31, 2025 deadline, rendering them non-compliant. This emphasizes the ongoing obligation of market authorization holders to ensure continuous regulatory compliance, with non-compliant products requiring fresh registration. Legal professionals must advise clients on these renewal requirements and the consequences of lapsed authorizations, which can impact import licenses and market access.

The PPB's emphasis on pharmacovigilance and the reporting of adverse events is also a crucial aspect of its safety communication strategy. The Board encourages healthcare providers and the public to report suspected adverse events through its electronic reporting system or via email, facilitating a robust feedback loop that informs future safety communications. This collaborative approach to safety monitoring underscores the shared responsibility in maintaining a safe pharmaceutical environment in Kenya.

The Pharmacy and Poisons Board's Safety Communications are indispensable instruments in Kenya's pharmaceutical regulatory framework, serving as critical alerts that protect public health and ensure the integrity of medicinal products. For practicing attorneys, understanding the nuances of these communications is paramount. Legal professionals advising pharmaceutical companies must ensure their clients have robust internal systems to promptly receive, interpret, and act upon all PPB directives, whether they pertain to product recalls, updated risk minimization measures, or changes in marketing authorization requirements. Failure to comply can result in significant legal and financial repercussions, including product liability claims, administrative sanctions, and damage to corporate reputation.

Healthcare providers, too, bear a direct responsibility to be vigilant and adhere to the guidance provided in these safety communications, as they directly impact patient care and professional liability. Attorneys representing healthcare practitioners should emphasize the importance of continuous professional development and awareness of the latest PPB advisories. As the PPB continues to strengthen its regulatory enforcement and embrace digital solutions, the legal landscape surrounding pharmaceutical safety will undoubtedly evolve. Practitioners should therefore remain attuned to these developments, including the ongoing efforts to achieve World Health Organization Maturity Level 3 for health products and technologies, which will likely lead to even more stringent regulatory oversight and communication protocols.